Mejorasp 3750 IU Injection
$356.57
$262.16
Mejorasp 3750 IU Injection is a specialized pharmaceutical treatment designed to combat various types of blood cancers, including Hodgkin's lymphoma. This powerful injection works by modulating the immune response and inhibiting cancer cell proliferation, making it an essential component in combination chemotherapy regimens. It is often administered alongside other anticancer agents to enhance therapeutic effectiveness and improve patient outcomes. Patients receiving Mejorasp should be monitored closely for potential side effects, which can include fatigue, nausea, and changes in blood cell counts. It is crucial to inform healthcare providers about any pre-existing conditions or medications being taken to minimize the risk of adverse reactions. As a vital tool in oncology, Mejorasp offers hope to those battling complex malignancies, but its use should always be guided by a qualified medical professional. With ongoing advancements in cancer treatment, Mejorasp remains an integral part of personalized care strategies, ensuring patients receive the most effective therapies available. Always consult with your healthcare team to understand how Mejorasp can best fit into your treatment plan.
मात्रा
Active Pharmaceutical Ingredient
Uses
• Mejorasp 3750 iu injection is primarily utilized in the treatment of acute lymphocytic leukaemia (ALL). This form of blood cancer primarily affects the white blood cells, leading to a rapid increase in their production. By administering Mejorasp 3750 iu injection, healthcare providers aim to manage the disease effectively and improve patient outcomes. It plays a critical role in the chemotherapy regimen for individuals diagnosed with this condition.
• In addition to its use in acute lymphocytic leukaemia, Mejorasp 3750 iu injection is also indicated for patients with non-Hodgkin's lymphoma (NHL). This type of cancer affects the lymphatic system and can vary significantly in its aggressiveness. Mejorasp 3750 iu injection helps to target and reduce the proliferation of cancerous cells, providing a vital option in the treatment plan. It is often part of a comprehensive approach to managing NHL, tailored to individual patient needs.
• Mejorasp 3750 iu injection is effective in enhancing the overall efficacy of cancer treatment protocols. It can be administered alongside other therapeutic agents to maximize the impact on blood cancers. The injection works by influencing the immune response and supporting the body's ability to combat malignant cells. This collaborative approach is essential for achieving better results in the management of conditions like ALL and NHL.
• Healthcare professionals may recommend Mejorasp 3750 iu injection in various clinical settings, especially when rapid intervention is necessary. Its role in the treatment of blood cancers highlights the importance of timely and appropriate care. By incorporating Mejorasp 3750 iu injection into treatment regimens, clinicians can provide patients with a valuable tool in their fight against cancer. This injection contributes significantly to the multidimensional strategies employed in oncological care.
Benefits
Blood cancer (acute lymphocytic leukemia): Blood cancer, known as leukemia, is a malignancy that affects the blood-forming tissues and impairs the body's immune response to infection. Administration of Mejorasp 3750 IU Injection inhibits the proliferation of cancer cells and effectively eradicates them. This Anti-cancer Drug Mejorasp has significant potency and toxicity, so a thorough discussion with your doctor regarding its potential risks and benefits is necessary. It is important to avoid alcohol during this treatment and to ensure adequate hydration by drinking plenty of water. Non-Hodgkin's lymphoma (NHL): Non-Hodgkin's lymphoma is a type of cancer that begins in your lymphatic system, which is a part of the body's germ-combating immune system. Administration of Mejorasp Injection inhibits the proliferation of cancer cells and effectively eradicates them. This medication has significant potency and toxicity, so a thorough discussion with your doctor regarding its potential risks and benefits is necessary. It is important to avoid alcohol during this treatment and to ensure adequate hydration by drinking plenty of water.
Side Effects
Like all medicines, Mejorasp 3750 IU Injection may cause side effects that do not require medical attention and which will disappear as your body adjusts to the medicine. Tell your doctor if they persist or if you're worried about them.
Most Common Side Effects
• Nausea
• Vomiting
• Weakness
• Loss of appetite
• Diarrhoea
• Epigastric pain
• Swelling over hands/ feet and ankles
• Injection site reaction ( like pain, redness, swelling)
• Irritability
Common Side Effects
• Drowsiness
• Acute Pancreatitis ( Pain in abdomen, unable to eat, swollen and tender abdomen, Rapid pulse)
• Headache
• Tiredness
• Irritability
• Stomach cramps
• Weight loss
How To Use
Mejorasp 3750 IU Injection is available in liquid form (injectable) for IM and IV use, which should be administered by a healthcare professional under medical supervision. The dosage and frequency of administration will be determined by your physician based on your medical condition and many other factors. Mejorasp Injection should not be self-administered.
Safety Advice
• Alcohol: Drinking alcohol while taking Mejorasp 3750 IU is generally not recommended. It may increase the risk of liver damage and it is best to avoid alcohol or to limit the amount of alcohol you drink while you are taking this medicine.
• Kidney: For patients with kidney impairment, dose adjustment is not recommended. Mejorasp Injection has not been studied in patients with severe renal impairment or in patients who are undergoing peritoneal dialysis or haemodialysis.
• Breastfeeding: Breastfeeding while taking Mejorasp Injection is not recommended as it may be harmful to the baby. The constituents of Mejorasp 3750 IU can potentially pass into breast milk and pose a risk to the baby. If you are currently breastfeeding and using Peg L-Asparaginase Injection 3750 IU, it is important to discuss the potential benefits and risks of continuing to breastfeed with your doctor. Your doctor will be able to advise you on how to ensure the optimum health of both you and your baby.
• Liver: For patients with mild liver disease, Mejorasp 3750 IU Injection is recommended. No dose adjustment is required in patients with mild liver impairment. However, Mejorasp 3750 IU is not recommended for use in patients with moderate or severe liver disease.
• Pregnancy: The use of Mejorasp 3750 IU Injection is not recommended in pregnant women as it may cause harm to the foetus if administered to a pregnant woman.
• Driving: It is uncommon for Mejorasp Injection to affect your driving skills.